Introduction
============

Cardiac fibroblasts form the largest population of interstitial cells in the adult mammalian heart ([@B7]). They have an essential role in the regulation of the extracellular matrix (ECM), which is crucial for maintaining the structural integrity of the myocardium and for electro-mechanical signal transduction ([@B3]; [@B60]). Cardiac fibroblasts are regulated by various mechanical and hormonal stimuli, in particular growth factors such as angiotensin II (ANGII) and the cytokine transforming growth factor β (TGFβ). ANGII and TGFβ can activate fibroblast cell-surface receptors to promote differentiation to myofibroblasts, the pro-fibrogenic phenotype that express the contractile protein α-smooth muscle actin (α-SMA) and exhibit enhanced secretory, migratory and proliferative properties ([@B56]; [@B48]; [@B32]; [@B49]; [@B37]). Following a myocardial infarction (MI), fibroblasts promote essential matrix deposition for proper tissue repair and scar formation to ensure structural integrity of the infarct zone. However, aberrant ECM deposition and excessive myofibroblast accumulation extending beyond the area of the original insult is responsible for maladaptive fibrosis leading to cardiac dysfunction, a hallmark feature of heart failure pathophysiology ([@B57]; [@B58]; [@B19]). Heart failure remains a major cause of mortality and morbidity in the western world with an estimated 50% 5 years survival rate after diagnosis ([@B41]). This highlights both the limitations of current therapeutic management and the crucial need for new and innovative therapies for the treatment and prevention of heart failure. Extracellular nucleotides and nucleosides have recently been implicated as important mediators of fibroblast homeostasis and as such purinergic signaling has been investigated for its role in cardiac fibrosis. AMP catabolites, including inosine and oxypurines have also been shown to contribute to cardiac fibrosis and diastolic stiffening in some animal models of heart failure ([@B45]). The role of nucleotide (ATP, ADP, UTP) signaling in tissue fibrosis has been comprehensively reviewed previously ([@B37]; [@B19]; [@B44]), therefore the current review will focus the modulation of cardiac fibrosis mediated by the nucleoside adenosine and adenosine receptors (ARs).

Adenosine Signaling in the Heart
================================

Adenosine is a ubiquitous purine nucleoside that is an important regulator of cardiac function. Adenosine is described as a 'retaliatory metabolite' owing to its enhanced local release and ability to restore energy balance during times of cellular and metabolic stress ([@B43]; [@B59]). The well-characterized cytoprotective actions have resulted in large clinical trials for adenosine and adenosine derivatives for the treatment of ischaemia-reperfusion injury post-MI ([@B31]; [@B53]; [@B20]). In addition to a clear role in cardioprotection, adenosine exerts a multitude of actions on the physiological regulation of the heart, including coronary vasodilation, heart rate control and AV nodal conduction, angiogenesis, myocardial hypertrophy and remodeling and fibrosis ([@B2]; [@B46]; [@B27]). The myriad of cardiovascular effects stimulated by adenosine occur via activation of specific cell surface ARs. The AR family is comprised of four Class A G protein-coupled receptors (GPCRs), the A~1~, A~2A~, A~2B~ and A~3~ARs. They exert distinct pharmacological actions through differential coupling to intracellular G proteins; the A~1~AR and A~3~AR preferentially activate G~i/o~ proteins to inhibit adenylyl cyclase activity and subsequent cAMP production, while the A~2A~AR and A~2B~AR preferentially stimulate G~s~ proteins to activate adenylyl cyclase activity and increase cAMP accumulation (**Figure [1](#F1){ref-type="fig"}**) ([@B21]). The A~2B~AR has also been shown to stimulate robust G~q/11~ protein activation in some cell types ([@B18]; [@B35]). ARs, and the A~2B~AR in particular, have also been shown to couple to additional transmembrane and intracellular proteins, which may influence downstream signal transduction ([@B42]; [@B21]; [@B63]). All four ARs are expressed in the heart and synchronous activation of multiple subtypes results in both complementary and opposing signal transduction for the fine-tuned regulation of cardiac function. Interestingly, both pro- and anti-fibrotic actions have been attributed to AR activation, which highlights both the complexity and ensuing challenges faced when targeting ARs for the treatment of cardiac fibrosis ([@B4]; [@B11]; [@B29]). To date, the preponderance of evidence has implicated the A~2B~AR in cardiac fibrosis ([@B16]; [@B27]; [@B44]). Therefore, this review will explore the current understanding of the role of AR signaling in augmenting or attenuating cardiac fibrosis, with a focus on the predominant subtype implicated, the A~2B~AR.

![**An overview of proposed adenosine receptor-mediated intracellular signaling pathways implicated in the regulation of cardiac fibrosis**.](fphar-08-00243-g001){#F1}

A~2B~AR-Mediated Anti-Fibrotic Signal Transduction
==================================================

Studies in isolated rat cardiac fibroblasts first proposed the A~2B~AR as the subtype responsible for mediating adenosine's inhibitory actions on fetal calf serum-stimulated fibroblast proliferation ([@B13]) and collagen and protein synthesis ([@B12]). The role of the A~2B~AR in adenosine-mediated anti-fibrotic signal transduction was later confirmed via antisense oligonucleotide A~2B~AR silencing, which resulted in increased cell proliferation and basal collagen synthesis in cardiac fibroblasts ([@B15]). Similarly, A~2B~AR overexpression had the opposite effect, significantly decreasing collagen and protein synthesis ([@B8]). The second messenger cAMP, has been shown to have a central role in inhibiting fibroblast and myofibroblast activity ([@B64]; [@B36]). Accordingly, A~2B~AR-mediated cAMP accumulation stimulated in fibroblasts by the non-selective AR agonist 5′-*N-*ethylcarboxamidoadenosine (NECA) ([@B16]) can reduce ANGII-stimulated collagen synthesis via an exchange factor directly activated by cAMP (Epac) and phosphoinositol-3 kinase (PI3K) dependent pathway (**Figure [1](#F1){ref-type="fig"}**) ([@B67]). In addition to effects on collagen synthesis, A~2B~AR stimulation has been shown to decrease mRNA expression of pro-fibrotic gene markers including collagen I and connective tissue growth factor (CTGF) ([@B66]). Of specific importance to ARs, a positive feedback loop has been identified whereby β-adrenoceptor-stimulated cAMP can be secreted by fibroblasts or cardiac myocytes and metabolized in the extracellular space to adenosine to activate A~2~ARs, thus exerting further inhibitory effects on fibroblast growth and function ([@B14]; [@B55]).

Commensurate with the *in vitro* findings, an *in vivo* study in rats demonstrated chronic administration of the stable adenosine analog, 2-chloroadenosine (CADO) or the adenosine uptake inhibitor, dipyridamole, initiated 1 week after permanent ligation of the left anterior descending (LAD) coronary artery, protected against cardiac remodeling and reduced markers of fibrosis such as collagen volume fraction and matrix metalloproteinase gene expression ([@B68]). The effects of CADO on fibrotic and haemodynamic parameters were abolished in the presence of the selective A~2B~AR antagonist MRS1754, but not selective antagonists for the other AR subtypes ([@B68]). Together, these studies suggest a salutary effect of A~2B~AR activation on cardiac fibrosis, an effect which may be lost upon A~2B~AR downregulation as observed in hearts taken from human patients with chronic heart failure ([@B1]).

A~2B~AR-Mediated Pro-Fibrotic Signal Transduction
=================================================

While the majority of *in vitro* studies have identified an anti-fibrotic role for the A~2B~AR, recent studies have demonstrated A~2B~AR blockade appears to be beneficial within *in vivo* models of cardiac remodeling and fibrosis. In an *in vivo* mouse model of MI involving permanent coronary artery ligation, chronic administration of a novel, highly selective A~2B~AR antagonist, GS-6201, significantly reduced cardiac enlargement and dysfunction compared to vehicle-treated mice ([@B65]). Similarly in an *in vivo* rat myocardial ischaemia-reperfusion model, GS-6201 improved ejection fraction and decreased fibrosis in the non-infarct and border zones with the greatest effect observed when GS-6201 was given 1 week rather 1 day after MI ([@B72]). A pro-fibrotic role for the A~2B~AR has been supported by a study in A~2B~AR knock-out (A~2B~AR^-/-^) mice that demonstrate the A~2B~AR contributes to post-infarction heart failure ([@B39]). A~2B~AR^-/-^ mice had improved end diastolic pressure and reduced interstitial fibrosis when compared to wild-type mice 8 weeks after permanent left coronary ligation. Systolic blood pressure and infarct size remained the same between knock-out and wild-type animals suggesting the A~2B~AR contributes to heart failure pathology via post-infarction remodeling and reactive fibrosis rather than acute cardioprotection ([@B39]). The mechanism underlying the pro-fibrotic activity of the A~2B~AR may involve the pro-inflammatory effects mediated by this AR subtype. Blockade of the A~2B~AR inhibits caspase-1 activity and leukocyte infiltrate ([@B65]), and attenuates secretion of pro-fibrotic and pro-inflammatory mediators such as TGFβ, tumor necrosis factor α (TNF-α) and interleukin-6 (IL-6) post-MI via a PKC-δ pathway (**Figure [1](#F1){ref-type="fig"}**) ([@B17]; [@B65]; [@B72]). A pro-inflammatory role of the A~2B~AR is reported by studies in other organ systems, in particular the lung where elevated adenosine concentrations and A~2B~AR activity promotes chronic fibrosis and inflammation in asthma and chronic obstructive pulmonary disease ([@B62]; [@B4]; [@B73]; [@B29]). Given the inflammatory response is intricately linked to the regulation of tissue fibrosis, it is perhaps unsurprising therefore, that the A~2B~AR has been implicated as a promoter of cardiac fibrosis *in vivo* ([@B24]; [@B30]; [@B61]).

A~1~AR Modulation of Cardiac Fibrosis
=====================================

The protective role of A~1~AR activation in cardiac remodeling appears to be largely attributed to the beneficial effects on cardiomyocyte hypertrophy rather than effects on fibrosis ([@B33]; [@B55]; [@B9]). A study using a non-selective adenosine analog (CADO) in mice subject to 4 weeks of chronic pressure overload via transverse aortic constriction (TAC), demonstrated reduced myocardial and perivascular fibrosis and hypertrophy compared to saline-treated mice ([@B33]). Attenuation of myocardial hypertrophy was A~1~AR-mediated, as the anti-hypertrophic effects were reversed in the presence of an A~1~AR-selective antagonist. As similar antagonist studies were not reported for measures of cardiac fibrosis ([@B33]), it cannot be ruled out that the anti-fibrotic effects were mediated by another AR subtype, in particular the A~2B~AR. However, recent studies using more A~1~AR-selective agonists do suggest an involvement of the A~1~AR in cardiac fibrosis. A study of heart failure in dogs demonstrated capadenoson, an A~1~AR partial agonist, decreased interstitial fibrosis ([@B54]). Similarly, activation of the A~1~AR with a selective agonist N^6^-cyclopentyladenosine (CPA), attenuated left ventricular collagen content and markers of fibrosis in response to α~1~-adrenergic stimulation *in vivo* ([@B50]).

Activation of the A~1~AR has been recognized as central to the acute cardioprotective actions of adenosine ([@B40]; [@B27]). In agreement, overexpression of the A~1~AR protects mice against acute ischaemic events, with cardiac infarct size markedly reduced in transgenic compared to wild-type animals ([@B71]). Paradoxically, however, chronic A~1~AR cardiac overexpression in older mice (20 weeks) has been associated with enhanced baseline cardiac fibrosis and dilated cardiomyopathy ([@B22]). Additionally, a study investigating myocardial fibrosis secondary to chronic renal failure demonstrated that an A~1~AR-selective antagonist, SLV320, normalized cardiac collagen I and III content in the hearts of rats that had undergone a nephrectomy ([@B28]). These studies may suggest chronic A~1~AR stimulation reduces the cardiac resistance to non-ischaemic stress and may promote fibrosis, however, the conflicting evidence highlights the need for further studies to fully elucidate the role of this AR subtype in cardiac fibrosis.

A~2A~AR Modulation of Cardiac Fibrosis
======================================

Separating the contribution of A~2B~AR-mediated fibrotic signaling from that of A~2A~AR activation has been difficult owing to the paucity of early subtype selective agonists and antagonists. Genetic alteration of the A~2A~AR demonstrated that cardiac-specific overexpression of the A~2A~AR in mice was protective against pressure-induced heart failure, attenuating fibrosis and improving cardiac function ([@B25]). A more recent study demonstrated high A~2A~AR expression in mouse cardiac fibroblasts stimulated the accumulation of the anti-fibrotic second messenger cAMP ([@B55]), though perhaps to a lesser extent than the A~2B~AR ([@B16]). Combined with the known anti-inflammatory actions of the A~2A~AR in the heart ([@B34]; [@B26]), there is certainly valid grounds to suggest that A~2A~AR signaling would attenuate cardiac fibrosis. However, further work is needed to clarify the exact role of A~2A~AR, as stimulation of this receptor subtype has also been demonstrated to have pro-fibrotic effects in other organs such as the liver and skin ([@B5],[@B6]; [@B47]).

A~3~AR Modulation of Cardiac Fibrosis
=====================================

Comparatively few studies have investigated the role of the A~3~AR in cardiac fibrosis, which is unsurprising given early studies examining the A~3~AR (and A~1~AR) expressed on isolated rat cardiac fibroblasts suggested these receptors to be of lesser functional importance than the A~2~ARs ([@B8]). The A~3~AR was investigated for its involvement in protecting against maladaptive cardiac hypertrophy and fibrosis on the basis that ecto-5′-nucleotidase (CD73; catalyzes the conversion of extracellular AMP to adenosine) deficiency exacerbated myocardial hypertrophy and heart failure in TAC mice ([@B69]). Contrary to hypothesis, A~3~AR knock-out mice actually had reduced left ventricular hypertrophy, fibrosis and dysfunction after 5 weeks of TAC compared to wild-type animals. There was no effect of A~3~AR deletion on parameters in the unstressed heart, suggesting the A~3~AR has a deleterious role in cardiac fibrosis only in response to chronic pressure overload ([@B38]). In agreement, a recent study using a uninephrectomy and high salt-induced model of hypertension in mice, demonstrated that genetic abrogation of the A~3~AR resulted in significantly less cardiac hypertrophy and fibrosis compared to wild-type animals ([@B70]). These studies suggest A~3~AR antagonism may be a valid therapeutic approach to prevent chronic pressure overload-hypertrophy and fibrosis, however, further studies are warranted.

Conclusion and Future Directions
================================

Cardiac fibrosis is an important determinant of left ventricular dysfunction and remodeling following MI and is a hallmark of heart failure pathology, which is associated with an extremely high rate of mortality ([@B57]; [@B58]). It is therefore crucial to find new therapeutic approaches to prevent and ideally reverse underlying cardiac fibrosis in order to modify the disease progression of heart failure. Purinergic signaling downstream of AR activation represents one such novel strategy to influence fibrosis homeostasis, however, much work is still needed to clarify the exact role of the receptor subtypes involved. A central question that remains is how the same receptor subtype can have both pro- and anti-fibrotic activity. The opposing effects as outlined in this review, may reflect differences in underlying disease pathology due to the type and duration of cardiac insult; whereby AR activation appears to be largely anti-fibrotic in acute ischaemic events but potentially pro-fibrotic under conditions of chronic myocardial stress. This supposition is supported by studies of adenosine's involvement in fibrosis of other organ systems ([@B29]). In the lung, A~2B~AR stimulation is protective in acute-bleomycin-induced lung injury but actually promotes fibrosis in chronic models of lung disease ([@B73], [@B74]). Similarly in the kidney, A~2B~AR activation is beneficial in attenuating acute kidney injury ([@B23]) but prolonged A~2B~AR signaling increases interstitial fibrosis and collagen deposition in renal tissue ([@B51],[@B52]). The exact mechanism behind these paradoxical effects requires further elucidation, but may reflect changes in differential receptor coupling with changes in cellular background as the disease progresses. Certainly, this idea is readily foreseeable for the A~2B~AR with its high degree of plasticity and ability to couple to multiple G proteins and intracellular signaling cascades (**Figure [1](#F1){ref-type="fig"}**) ([@B10]). In addition, it should be noted a great deal of our understanding of adenosine's role in cardiac fibrosis, in particular downstream of A~2B~AR, has come from *in vitro* studies. This may not reflect the true course of disease progression *in vivo* due to the exclusion of the inflammatory response and loss of organ complexity including cross-talk with other cell types. Therefore, while AR signaling appears to be a promising target in cardiac fibrosis, further studies are needed to fully appreciate the potential of AR therapeutics in heart failure and underlying fibrosis.
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